Infection, Bacterial Clinical Trial
Official title:
Comparison of the Efficacy of Sterile Gauze and Semi-permeable Film Dressing for Hemodialysis Non-tunneling Central Venous Catheter
This prospective single center RCT aims to compare sterile gauze and tape versus Semi-permeable film dressing on the incidence of exit-site infection, CRBSIs (catheter-related bloodstream infections), skin irritation, total bacterial count, dressing intactness and cost-benefit, nursing workload in hemodialysis patients with a non-tunneled hemodialysis catheter.
Status | Recruiting |
Enrollment | 154 |
Est. completion date | December 31, 2022 |
Est. primary completion date | May 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - age more than 18 years; requiring hemodialysis treatment by non-tunneled CVC inserted through subclavian vein, femoral vein, internal jugular vein by nephrologists team, allowing sufficient blood flow; competent to provide informed consent. Exclusion Criteria: - current systemic antibiotic therapy as a result of bacteremia in the previous 21 days; pregnancy; with a known dermatitis at the exit site or known hypersensitivity to a component of either dressing; require antibiotic lock or antibiotic ointment in exit-site for infection prevention locally |
Country | Name | City | State |
---|---|---|---|
China | Peking University People's Hospital | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Peking University People's Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | exit-site infection | redness, tenderness, swelling and/or with exudation within 2 cm around exit of CVC in the skin | before disinfectant and dressing change at every hemodialysis session within 2 weeks | |
Secondary | catheter-related blood stream infection(CRBSI) | At least one blood culture from peripheral venous puncture was collected at CVC removal and whenever a catheter-related infection or other type of sepsis was suspected (temperature 38.2°C or 36.5°C or chills, leukocytes 10,000 or 4,000, or other signs of sepsis according the diagnosis of CDC | within 2-week follow-up or before withdrawn of hemodialysis therapy if the patient cannot reach 2 weeks | |
Secondary | skin erythema and dryness under the dressing area | The following scale was used for erythema [modified from Fitzpatrick et al. (20)]: 0 ¼ none; 0.5 ¼ equivocal erythema; 1 ¼ slight redness, spotty and diffuse; 2 ¼ moderate uniform redness; 3 ¼ intense redness; 4 ¼ fiery red with oedema.The following scale was used for dryness:0 ¼ none; 1 ¼ slight scaling, dryness; 2 ¼ moderate scaling, dryness; 3 ¼ severe dryness with large flakes. The sum score of dryness and erythema over all assessment times served as outcome parameter. | before disinfectant and dressing change at every hemodialysis session within 2 weeks | |
Secondary | total bacterial count | cotton swab in skin within 2 cm around the exit-site of CVC under the dressing | Once only. At the time of the 2nd dressing change after CVC insertion of each patient(dressing change usually happened at each hemodialysis therapy session) | |
Secondary | dressing intactness | if all the corners or edges of dressing is intact, count how many corners or edges rolled up or fell off | before disinfectant and dressing change at every hemodialysis session within 2 weeks | |
Secondary | nursing time for dressing change | how much time a dressing change procedure cost in minutes. Nursing time are recorded by other nurse using a clock while the nurse change dressing for a patient.the whole time cost of the nurse doing dressing change should be the outcome. | at any of the session, once only |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05846399 -
CAT BITE Antibiotic Prophylaxis for the Hand/Forearm (CATBITE)
|
Phase 4 | |
Recruiting |
NCT05904535 -
Novel Diagnostic Methods to Identify External Ventricular Drain Associated Infections
|
||
Not yet recruiting |
NCT04075344 -
Effect of a Infection Control Program on the Reduction of Bacterial Contamination on NG Tube Feeding in RCHEs
|
N/A | |
Completed |
NCT05333133 -
High Calorie Formula Intervention on Weight, Length Increment, Total Lymphocyte Counts, TNF-alpha and IGF-1 in Failure to Thrive Children
|
N/A | |
Recruiting |
NCT05950984 -
Medical Device (MD) Derived Pharmacokinetic (PK) Parameters for Vancomycin (MD-PK)
|
||
Recruiting |
NCT06283433 -
A Dried Blood Spot Sampling Method for Vancomycin and Creatinine Monitoring for OPAT
|
N/A | |
Recruiting |
NCT06178822 -
Towards Novel BIOmarkers to Diagnose SEPsis on the Emergency Room
|
||
Completed |
NCT03688321 -
Probiotic on Prevention of GBS Vaginal Infection During Pregnancy
|
N/A | |
Completed |
NCT03244917 -
Trial to Reduce Antimicrobial Use In Nursing Home Residents With Alzheimer's Disease and Other Dementias
|
N/A | |
Recruiting |
NCT04450680 -
Beta-lactam Therapeutic Drug Monitoring in Singapore
|
||
Completed |
NCT05686577 -
How to Reduce Unnecessary Blood Cultures: Construction and Validation of a Predictive Score for Blood Culture Positivity in Intensive Care
|
||
Recruiting |
NCT06093269 -
Pharmacokinetics Study of Cefazolin in Hemodialysis (CEFAZODIAL)
|
Phase 4 | |
Recruiting |
NCT05587283 -
Safety, Tolerability, and Acceptability Study of Intravaginal Administration of LABTHERA-001 Capsules in Healthy Women
|
Phase 1 | |
Recruiting |
NCT03752424 -
Topical Silver Nanoparticles for Microbial Activity
|
Phase 1 | |
Completed |
NCT04440631 -
Gut Microbiome of Patients Undergoing Antibiotic Therapy for Orthopedic Device-related Infection
|
||
Active, not recruiting |
NCT05150015 -
ElastoMeric Infusion Pumps for Hospital AntibioTICs
|
N/A | |
Completed |
NCT03816956 -
Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301
|
Phase 3 | |
Terminated |
NCT03555981 -
Early Kangaroo Mother Care in Gambian Hospitalised Unstable Neonates
|
N/A | |
Completed |
NCT03133312 -
Chlorhexidine Gluconate Versus Povidone-Iodine as Vaginal Preparation Antiseptics Prior to Cesarean Delivery
|
Phase 4 | |
Completed |
NCT03925402 -
Ertapenem for Initial Empirical Treatment of Third Generation Cephalosporin Resistant Enterobacteriaceae Bacteremia
|